相关实验视频

Updated: Jan 15, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

使用多层次计算查和模拟识别有效的循环素依赖性激酶3/循环素E抑制剂

Srutishree Sarma¹, Dikshita Dowerah², Shilpa Neog¹

¹CMML-Catalysis and Molecular Modelling Lab, Department of Chemical Sciences, Tezpur University, Napaam, 784028, Sonitpur, Assam, India.

Computers in biology and medicine

|October 9, 2025

概括

研究人员确定CID_25211747是循环素依赖激酶3 (CDK3) 的强有力的抑制剂,这是癌症治疗的关键标. 这一发现为开发有效的CDK3抗剂和未来的癌症治疗提供了有希望的新方向.

科学领域:

生物化学生物化学
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

循环素依赖激酶3 (CDK3) 调节细胞循环的进展.
在各种癌症中,CDK3的过度表达呈现出治疗标.
目前,没有特定的CDK3抑制剂可用.

研究的目的:

为了确定有效的CDK3/环素E抑制剂.
通过计算对204种CDK3抑制剂衍生物的库进行选.
提名一种化合物用于开发CDK3抗剂.

主要方法:

使用了包括分子对接在内的多层计算管道.
执行了ADMET分析,全球反应性研究和分子动力学 (MD) 模拟.
使用N层集成分子轨道和分子力学 (ONIOM) 计算用于结合亲和力分析.

主要成果:

确定了顶级候选人和关键的CDK3残留物之间的相互作用.
MD模拟和ONIOM计算证实了稳定的联体受体相互作用和有利的结合能.
扩展模拟突出了CID_25211747.7的特殊稳定性和强大的结合亲和力.

结论:

CID_25211747 证明了对CDK3.3的最佳抑制和稳定性.
该化合物显示为开发新型CDK3抗剂的前沿.
为未来针对CDK3.3的抗癌药物设计提供了宝贵的见解.

关键词:

CDK3 / 环素 E 的使用.癌症癌症癌症癌症停靠的对接方式抑制剂的抑制剂分子动力学分子动力学这就是ONIOM的意义.

更多相关视频

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries

Published on: January 22, 2019

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Positive Regulator Molecules

Positive Regulator Molecules

Mitotic cell division results in daughter cells that exactly resemble the parent cell. However, errors in the DNA replication or distribution of genetic material may lead to genetic mutations that may be passed down to every new cell formed from the resulting abnormal cell. Propagation of such mutant cells is restricted through checkpoint mechanisms present at different stages of the cell cycle. These checkpoints involve regulator molecules that either promote or demote cell cycle events.

M-Cdk Drives Transition Into Mitosis

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...